---
title: "CSPC PHARMA  Shares Rise 15% as Phase Ib/II Clinical Trial of SYS 6090 Injection for Hepatocellular Carcinoma Launches at First Center in China"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296423040.md"
description: "CSPC PHARMA shares surged nearly 15% after announcing the launch of its Phase Ib/II clinical trial for SYS 6090 Injection, a novel PD-1/IL-15 fusion protein for hepatocellular carcinoma. The drug targets tumor-infiltrating immune cells to block immunosuppression and activate immune responses. Preclinical data indicated significant tumor inhibition and favorable safety profiles compared to existing therapies."
datetime: "2026-08-20T02:01:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296423040.md)
  - [en](https://longbridge.com/en/news/296423040.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296423040.md)
generator: "portal-rs"
---

# CSPC PHARMA  Shares Rise 15% as Phase Ib/II Clinical Trial of SYS 6090 Injection for Hepatocellular Carcinoma Launches at First Center in China

CSPC PHARMA (01093.HK) +1.275 (+14.680%) Short selling $81.69M; Ratio 13.872% opened 9.38% higher today and once reached HKD10.04. The stock was last reported at HKD9.985, up 14.97%, with trading volume of 136 million shares involving HKD1.342 billion.

CSPC PHARMA announced that the Phase Ib/II clinical trial of SYS 6090 Injection developed by the group for the treatment of hepatocellular carcinoma has officially commenced at the first clinical center in China.

The product is classified as a Class 1 therapeutic biological product registration and is a recombinant fully human anti-programmed cell death protein 1 fusion protein combined with interleukin-15. Through its left arm, it targets PD-1 positive tumor-infiltrating immune cells and blocks the immunosuppressive function caused by the interaction between PD-1 and programmed death ligand 1 (PD-L1). At the same time, through its right arm, it binds to the IL-15 receptor and activates downstream signaling pathways, further promoting the activation and proliferation of related immune cells. Preclinical study results showed that the product could significantly inhibit tumor growth, demonstrated favorable safety and tolerability, and showed higher pharmacological activity compared with other PD-1 monoclonal antibody drugs and IL-15 drugs.(sl/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-19 16:25.)

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [CSPC PHARMA  1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18](https://longbridge.com/en/news/296435690.md)
- [CSPC Pharma FY26 H1 profit attributable to shareholders more than doubled to RMB 6.09 billion; revenue rises 40.1% to RMB 18.59 billion](https://longbridge.com/en/news/296433558.md)
- [M Stanley Raises CSPC PHARMA  TP to HKD12, Rating Overweight](https://longbridge.com/en/news/296557755.md)
- [Leads Biolabs touts promising Phase II data for NSCLC bispecific antibody LBL-024](https://longbridge.com/en/news/296415546.md)
- [Gentian Diagnostics hosts webinar on circulating calprotectin use in rheumatic disease management](https://longbridge.com/en/news/296439040.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**